NCT05128591View on ClinicalTrials.gov

A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 9, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Embolism and Thrombosis
Interventions
DRUG

Rivaroxaban 18mg Oral Tablet

AD-109 (Rivaroxaban 18mg) Oral Tablet

DRUG

Rivaroxaban 20 MG Oral Tablet

AD-1091 (Rivaroxaban 20mg) Oral Tablet

Trial Locations (1)

Unknown

H+ Yangji Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT05128591 - A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091 | Biotech Hunter | Biotech Hunter